

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 05, 2022**

**Adicet Bio, Inc.**

(Exact name of Registrant as Specified in Its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38359**  
(Commission File Number)

**81-3305277**  
(IRS Employer  
Identification No.)

**200 Berkeley Street, 19th Floor**  
**Boston, Massachusetts**  
(Address of Principal Executive Offices)

**02116**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (650) 503-9095**

**Not applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.0001 per share	ACET	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On October 5, 2022, Adicet Bio, Inc. published to its website an updated pipeline chart of its product candidates in development, which is filed as Exhibit 99.1 hereto and incorporated by reference herein.

**Item 9.01 Exhibits.**

(d) Exhibits

**Exhibit****Number****Description**

99.1

[Adicet Bio, Inc. Pipeline chart as of October 5, 2022.](#)

104

Cover Page Interactive Data File (embedded within the Inline XBRL Document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


**ADICET BIO, INC.**

Date: October 5, 2022

By: /s/ Nick Harvey  
Name: *Nick Harvey*  
Title: *Chief Financial Officer*

---

# Building a Broad Pipeline of First-in-Class $\gamma\delta$ CAR T Cell Therapy



\* Regeneron exercised its option to license the exclusive worldwide rights to ADI-002  
 HCC= Hepatocellular carcinoma; mCRPC= Metastatic castration-resistant prostate cancer; MICA/MICB = Major histocompatibility complex (MHC) Class I chain-related protein A/B;  
 NHL= Non-Hodgkins lymphoma; PSMA= Prostate-specific membrane antigen; RCC= Renal cell carcinoma; ST=Solid tumor; ULBP=UL16 binding protein



